The Company has generic formulation and API business interests in over 80 countries across the world including the highly regulated markets of USA and Europe. The formulation business spans several product segments such as Dermatology, Internal Medicine, Pediatrics, Gynecology, ENT, Cardiology, Diabetes and Oncology.
Glenmark's first Asthma/COPD molecule, Oglemilast [GRC 3886], was
licensed out to Forest Laboratories and Teijin Pharma Limited for the North
American and Japanese markets, respectively, in two landmark deals. The
Company's second lead GRC 8200, a DPP-IV inhibitor for Type II Diabetes was
out-licensed to Merck KGaA, Germany for the North American, European and
Japanese markets. A third molecule targeting pain, GRC 6211, undergoing
Phase 2 clinical trials in Europe, has recently been out-licensed to Eli
Lilly & company.
For further information, please contact:
Ms. Vasudha Jha
General Manager, Corporate Communications
Glenmark Pharmaceuticals Ltd.
Tel: [+91 22] 40189919 | Fax: [+91 22] 40189986
Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a medicinal plant which can be sustainably harvested from several countries in South America. Crofelemer is in various stages of clinical development for four distinct product indications, one in Phase 3, two in Phase 2 and one in Phase 1.
Crofelemer has been tested in trials involving approximately 1500
patients in double-blind placebo-controlled, mostly published t
|SOURCE Napo Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved